Experimental cancer pill tested in advanced tumors – trial halted early

NCT ID NCT04892017

Terminated Disease control Sponsor: Deciphera Pharmaceuticals, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called DCC-3116 (inlexisertib) in 91 people with advanced or metastatic solid tumors that have RAS/MAPK pathway mutations. The drug was given alone or combined with other targeted therapies. The study aimed to find safe doses and check for side effects, but it was terminated early. It is unclear if the drug will move forward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DCC-3116 (inlexisertib) taken as a pill, alone or with other targeted drugs (trametinib, binimetinib, or sotorasib)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific genetic mutations.
What could go wrong: This was a very early (phase 1/2) trial that was terminated, meaning it stopped early. It involved only 91 participants, so results may not apply widely, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

New York, New York, 10016, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
NEXT Oncology

Austin, Texas, 78758, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Rutgers Cancer Institute

New Brunswick, New Jersey, 08901, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Wisconsin Clinical Science Center

Madison, Wisconsin, 53792, United States
Washington University Siteman Cancer Center

St Louis, Missouri, 63108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.